205 related articles for article (PubMed ID: 11257709)
1. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1.
Boyle BJ; Zhao XY; Cohen P; Feldman D
J Urol; 2001 Apr; 165(4):1319-24. PubMed ID: 11257709
[TBL] [Abstract][Full Text] [Related]
2. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
Stewart LV; Weigel NL
Prostate; 2005 Jun; 64(1):9-19. PubMed ID: 15651061
[TBL] [Abstract][Full Text] [Related]
3. The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells.
Peng L; Wang J; Malloy PJ; Feldman D
Int J Cancer; 2008 Feb; 122(3):558-66. PubMed ID: 17918155
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway.
Murthy S; Weigel NL
Prostate; 2004 May; 59(3):282-91. PubMed ID: 15042604
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells.
Peng L; Malloy PJ; Wang J; Feldman D
Endocrinology; 2006 Oct; 147(10):4599-607. PubMed ID: 16825320
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells.
Rao A; Coan A; Welsh JE; Barclay WW; Koumenis C; Cramer SD
Cancer Res; 2004 Mar; 64(6):2143-7. PubMed ID: 15026355
[TBL] [Abstract][Full Text] [Related]
8. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
10. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter.
Peng L; Malloy PJ; Feldman D
Mol Endocrinol; 2004 May; 18(5):1109-19. PubMed ID: 14963110
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
Moffatt KA; Johannes WU; Hedlund TE; Miller GJ
Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells.
Martin JL; Pattison SL
Endocrinology; 2000 Jul; 141(7):2401-9. PubMed ID: 10875240
[TBL] [Abstract][Full Text] [Related]
13. Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells.
Tsubaki J; Hwa V; Twigg SM; Rosenfeld RG
Endocrinology; 2002 May; 143(5):1778-88. PubMed ID: 11956160
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells.
Gucev ZS; Oh Y; Kelley KM; Rosenfeld RG
Cancer Res; 1996 Apr; 56(7):1545-50. PubMed ID: 8603400
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
Golovko O; Nazarova N; Tuohimaa P
Life Sci; 2005 Jun; 77(5):562-77. PubMed ID: 15904673
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
18. Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells.
Goossens K; Esquenet M; Swinnen JV; Manin M; Rombauts W; Verhoeven G
Mol Cell Endocrinol; 1999 Sep; 155(1-2):9-18. PubMed ID: 10580834
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth and increased expression of insulin-like growth factor-binding protein-3 (IGFBP-3) and -6 in prostate cancer cells stably transfected with antisense IGFBP-4 complementary deoxyribonucleic acid.
Drivdahl RH; Sprenger C; Trimm K; Plymate SR
Endocrinology; 2001 May; 142(5):1990-8. PubMed ID: 11316765
[TBL] [Abstract][Full Text] [Related]
20. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
